Does Rallies show Form 4 insider transactions for NUVL?

Yes. Rallies tracks NUVL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NUVL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NUVL. It does not provide personalized investment advice.

NUVL (Nuvalent, Inc. Class A Common Stock) Stock Analysis - Insider Trades

Nuvalent, Inc. Class A Common Stock (NUVL) is a publicly traded Healthcare sector company. As of May 21, 2026, NUVL trades at $102.31 with a market cap of $7.89B and a P/E ratio of -17.40. NUVL moved +1.30% today. Year to date, NUVL is +4.47%; over the trailing twelve months it is +34.84%. Its 52-week range spans $55.54 to $113.02. Analyst consensus is strong buy with an average price target of $140.85. Rallies surfaces NUVL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NUVL stock inside the company?

Recent NUVL insider activity includes Miller Deborah Ann sold 4.42K, Miller Deborah Ann sold 1.08K, Noci Darlene sold 4.50K, Noci Darlene sold 700, and Noci Darlene sold 300. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NUVL Key Metrics

Key financial metrics for NUVL
Metric	Value
Price	$102.31
Market Cap	$7.89B
P/E Ratio	-17.40
EPS	$-5.85
Dividend Yield	0.00%
52-Week High	$113.02
52-Week Low	$55.54
Volume	775
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-425.38M
Gross Margin	0.00%

Recent NUVL Insider Trades

Miller Deborah Ann sold 4.42K (~$437.96K) on Apr 30, 2026.
Miller Deborah Ann sold 1.08K (~$107.73K) on Apr 30, 2026.
Noci Darlene sold 4.50K (~$447.07K) on Apr 29, 2026.
Noci Darlene sold 700 (~$70.10K) on Apr 29, 2026.
Noci Darlene sold 300 (~$30.35K) on Apr 29, 2026.

Latest NUVL News

Nuvalent drops as Q1 results and FDA program updates hit tape — May 7, 2026
Nuvalent climbs as Guardant diagnostic partnership and ASCO catalyst focus returns — May 4, 2026
Nuvalent slides as FDA zidesamtinib NDA review and AACR data spark profit-taking — Apr 26, 2026
Nuvalent slides 3% as profits are taken ahead of May 7 earnings — Apr 25, 2026
Nuvalent slides as biotech risk-off hits, after ASCO catalyst and April FDA filing — Apr 24, 2026

NUVL Analyst Consensus

14 analysts cover NUVL: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $140.85.

Common questions about NUVL

Who is trading NUVL stock inside the company?: Recent NUVL insider activity includes Miller Deborah Ann sold 4.42K, Miller Deborah Ann sold 1.08K, Noci Darlene sold 4.50K, Noci Darlene sold 700, and Noci Darlene sold 300. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NUVL?: Yes. Rallies tracks NUVL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NUVL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NUVL. It does not provide personalized investment advice.